Macrogenics has the GF Score of 47, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Macrogenics
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Macrogenics (FRA:M55) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Macrogenics GF Score Related Terms
FRA:M55 vs IMRX, TRDA, SLNCF: GF Score Comparison
For the Biotechnology subindustry, Macrogenics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Macrogenics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Macrogenics's GF Score distribution charts can be found below:
* The bar in red indicates where Macrogenics's GF Score falls into.
Macrogenics (FRA:M55) has a GF Score of 47 as of Jul. 09, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Macrogenics and its competitors. This is 18% below median its historical median of 57.00. Over the past decade, Macrogenics' GF Score has ranged from 17.00 to 77.00.
Is Macrogenics' GF Score too high?
Macrogenics' current GF Score of 47 is 18% below median its 10-year median of 57.00. Over the past 10 years, this metric has ranged from a low of 17.00 to a high of 77.00. Overall, Macrogenics has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' GF Score compare to IMRX and TRDA?
Macrogenics' GF Score of 47 can be compared against companies in the Biotechnology industry. Historically, Macrogenics' own GF Score has ranged from 17.00 to 77.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Macrogenics and its competitors. Macrogenics's current GF Score is 47, which is 18% below median its own 10-year median of 57.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (FRA:M55) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €4.12 — trading 14.8% above its estimated fair value. The current GF Score is 47, which is 18% below median its 10-year median of 57.00. Macrogenics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current GF Score is 47 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Macrogenics (FRA:M55) Overvalued in 2026?
Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued.
The current stock price of €4.12 is trading 14.8% above its estimated GF Value™ of €3.59.
GuruFocus considers Macrogenics to be Modestly Overvalued.
Key valuation signals for FRA:M55:
GF Score: 47 (18% below median its 10-year median of 57.00)
GF Value™: €3.59 vs. price of €4.12 (14.8% above fair value)
No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
47GF Score
Get the complete analysis for FRA:M55
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M55 has been successfully added to your 